Limited upside, IMO. I worked in hospital pharmacies when I was putting myself through college, so I know a bit about that business. The drug addiction treatment is just a reformulation and different delivery system, and even if it gets approved, it will still be competing against the generic version of that drug (buprenorphine). It may run a bit more until the rule on it, but it'll probably sell off after approval (as many biotechs do). Just my opinion. GL.